To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Soluble Levels of CD163, PD-L1, and IL-10 in Renal Cell Carcinoma Patients
Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Urology.ORCID iD: 0000-0002-2850-6009
Department of Urology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Urology.ORCID iD: 0000-0001-5533-7899
Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Urology.ORCID iD: 0000-0003-0162-5881
2022 (English)In: Diagnostics, ISSN 2075-4418, Vol. 12, no 2, article id 336Article in journal (Refereed) Published
Abstract [en]

CD163+ M2 macrophages have been suggested to counteract tumor immunity by increasing immunosuppressive mechanisms including PD-L1 and IL-10 expression. Soluble levels of PD-L1, IL-10, and CD163 have been reported as potential biomarkers in various cancers, although the prognostic value in renal cell carcinoma (RCC) has to be further elucidated. In the present study, we measured the levels of sPD-L1, sIL-10, and sCD163 in 144 blood samples from patients with RCC. The levels were determined by using enzyme linked immunosorbent assays. Soluble PD-L1 and CD163 were detectable in 100% of the serum samples, and sCD163 in 22% of the urine samples, while only a minority of the samples had detectable sIL-10. Significantly higher serum levels of sPD-L1 and sCD163 were observed in patients with metastatic disease (p < 0.05). The results also showed that patients with high levels of sPD-L1 in serum had shorter cancer-specific survival compared with patients with low levels (p = 0.002). The results indicate that sPD-L1 most significantly reflects tumor progression in RCC.

Place, publisher, year, edition, pages
MDPI, 2022. Vol. 12, no 2, article id 336
Keywords [en]
liquid biopsy, renal cell carcinoma, sCD163, sIL-10, sPD-L1
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-97692DOI: 10.3390/diagnostics12020336ISI: 000764022500001PubMedID: 35204426Scopus ID: 2-s2.0-85124074574OAI: oai:DiVA.org:oru-97692DiVA, id: diva2:1640921
Available from: 2022-02-28 Created: 2022-02-28 Last updated: 2022-03-16Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Davidsson, SabinaCarlsson, JessicaSundqvist, Pernilla

Search in DiVA

By author/editor
Davidsson, SabinaCarlsson, JessicaSundqvist, Pernilla
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
Diagnostics
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 48 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf